The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model

This publication has 30 references indexed in Scilit:

• Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial
  The Lancet, 1999
• A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes
  New England Journal of Medicine, 1996
• Hirudin in Acute Myocardial Infarction
  Circulation, 1996
• Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)
  Circulation, 1994
• Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.
  Circulation, 1994
• Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.
  Circulation, 1994
• Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4.
  Circulation, 1994
• Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
  Journal of Clinical Investigation, 1990
• Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties.
  Journal of Clinical Investigation, 1989
• Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.
  Proceedings of the National Academy of Sciences, 1989